Celltrion, Inc. (KRX:068270)
South Korea · Delayed Price · Currency is KRW | Market Cap | 43.77T +10.8% |
| Revenue (ttm) | 4.90T +30.6% |
| Net Income | 1.58T +220.3% |
| EPS | 6,840.22 +226.4% |
| Shares Out | 228.43M |
| PE Ratio | 28.01 |
| Forward PE | 28.06 |
| Dividend | 714.29 (0.37%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 580,702 |
| Open | 191,200 |
| Previous Close | 189,300 |
| Day's Range | 188,200 - 193,500 |
| 52-Week Range | 158,500 - 239,048 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 270,666.67 (+41.27%) |
| Est. Earnings | Nov 13, 2026 |
About Celltrion
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and u... [Read more]
Financial Performance
In 2025, Celltrion's revenue was 4.16 trillion, an increase of 17.01% compared to the previous year's 3.56 trillion. Earnings were 1.03 trillion, an increase of 143.58%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for 068270 stock is "Buy." The 12-month stock price target is ₩270,667, which is an increase of 41.27% from the latest price.
News
Celltrion Q3 Earnings Fall
(RTTNews) - Celltrion, Inc. (068270.KS), a biopharmaceutical company, reported a decline in net income on Tuesday despite higher third-quarter 2026 sales than the previous year.
Celltrion Slides: Q3 2026
Celltrion has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 27, 2026.
Celltrion To Present ZYMFENTRA Data On Treatment Resumption And Crohn's Outcomes At ACG 2026
(RTTNews) - Celltrion USA, Inc., the U.S. subsidiary of Celltrion Inc. (068270.KS), will present two new analyses of ZYMFENTRA in patients with Crohn's disease and ulcerative colitis at the American C...
Celltrion Quarterly report: Q2 2026
Celltrion has published its Q2 2026 quarterly earnings report on August 13, 2026.
Celltrion Slides: Q2 2026
Celltrion has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Celltrion Q2 Operating Income Jumps
(RTTNews) - Celltrion, Inc. (068270.KS), a biopharmaceutical company, on Friday reported higher operating income and sales in the second quarter of 2026 compared with the same period last year.
Celltrion Slides: Investor presentation
Celltrion has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Celltrion Slides: Q1 2026
Celltrion has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Celltrion Quarterly report: Q1 2026
Celltrion has published its Q1 2026 quarterly earnings report on May 6, 2026.
Celltrion Q1 Net Income Rises
(RTTNews) - Celltrion (068270.KS) reported first quarter net income attributable to shareholders of the parent company of 346.14 billion Korean won, an increase of 218.54% year-over-year from 108.67 b...
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA ® (infliximab-dy...
Celltrion Slides: Investor presentation
Celltrion has posted slides in relation to its latest quarterly earnings report, which was published on March 28, 2026.
Celltrion Enters Contract Manufacturing Agreement With Global Pharmaceutical Company
(RTTNews) - Celltrion (068270.KS) has signed a contract manufacturing agreement with a global pharmaceutical company for the supply of drug substance. Celltrion will supply drug substance for three ye...
Celltrion Announces Commercial Availability In US Of AVTOZMA SC, Tocilizumab Biosimilar
(RTTNews) - South Korean biopharmaceutical company Celltrion, Inc. (068270.KS) announced Monday that AVTOZMA (tocilizumab-anoh) subcutaneous (SC) formulation is now commercially available to patients ...
Celltrion Annual report: Q4 2025
Celltrion has published its Q4 2025 annual report on March 16, 2026.
Celltrion Slides: Q4 2025
Celltrion has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 16, 2026.
Celltrion Reports Post-hoc Analysis From LIBERTY Studies
(RTTNews) - Celltrion (068270.KS) announced new data from a post-hoc analysis of the LIBERTY studies, showing that subcutaneous infliximab restored and maintained response in most Crohn's disease and ...
Celltrion Slides: Investor presentation
Celltrion has posted slides in relation to its latest quarterly earnings report, which was published on January 5, 2026.
Celltrion Slides: Investor presentation
Celltrion has posted slides in relation to its latest quarterly earnings report, which was published on January 5, 2026.
FDA Clears New Prefilled Syringe Of Celltrion's OMLYCLO, Interchangeable Biosimilar To XOLAIR
(RTTNews) - Celltrion Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO (omalizumab-igec)—the first and only biosimilar designated as interchan...
Celltrion Slides: Q3 2025
Celltrion has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 14, 2025.
Celltrion Quarterly report: Q3 2025
Celltrion has published its Q3 2025 quarterly earnings report on November 14, 2025.
Celltrion Slides: Investor presentation
Celltrion has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2025.
FDA Approves Celltrion's EYDENZELT, Biosimilar To EYLEA, For Multiple Retinal Conditions
(RTTNews) - Celltrion Inc. announced that the U.S. Food and Drug Administration approved EYDENZELT (aflibercept-boav), biosimilar referencing EYLEA (aflibercept), for the treatment of neovascular (wet...
Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal
Asian drug stocks faced a downturn. This followed US President Trump's tariff threat on imported pharmaceuticals. South Korean and Japanese drugmakers experienced declines. Samsung Biologics and Sumit...